Acute ischaemic stroke
The current guideline is AHA/ASA 2026. It replaces the 2018 guideline and its 2019 update, and covers care from the ambulance to early secondary prevention.
What changed from 2019
- Tenecteplase (0.25 mg/kg) is now an equal first choice to alteplase.
- Disabling deficit, not NIHSS, decides IVT. Mild non-disabling deficits get DAPT, not IVT.
- Contraindications are graded (absolute, relative, benefit usually greater) instead of a fixed list. Remote GI bleeding, remote MI, extra-axial tumours and unruptured aneurysms are no longer reasons to withhold IVT.
- EVT for large cores (ASPECTS 0–5) and basilar occlusion (NIHSS ≥10).
- Children: first recommendations for IVT and EVT.
- Lower targets backfire: intensive BP lowering after EVT is harmful; tight glucose control (80–130 mg/dL) gives no benefit.
Clinical pearls
- ABCD2 score (TIA risk): Age ≥60, BP ≥140/90, Clinical features (weakness 2, speech only 1), Duration (≥60 min 2, 10–59 min 1), Diabetes. ≥4 is high risk.
- ASPECTS scores 10 MCA regions on CT, subtracting 1 for each with early ischaemic change; 10 is normal.
- Cerebellar infarct volume ≥35 mL or brainstem compression: suboccipital craniectomy.